Paraneoplastic Cerebellar Degeneration with Anti-Yo Antibody in a Patient with Fallopian Tube Adenocarcinoma: A Case Report and Literature Review

Jirayu Sae-Chan, Supakorn Yamuthai, Thanyalak Amornpojnimman, Prut Koonalinthip

Abstract

Paraneoplastic cerebellar degeneration (PCD) typically presents via acute to subacute cerebellar ataxia, dysarthria, and ocular dysmetria, resulting from tumor-induced autoimmunity against the cerebellum. In most cases, symptoms of PCD show months before a diagnosis of cancer. Therefore, it is important for clinicians to investigate the primary tumor in PCD cases in order to treat both conditions concurrently. Herein, we report a case of PCD associated with an anti-Yo antibody, leading to a diagnosis of left fallopian tube adenocarcinoma.

 Keywords

anti-Yo antibody; gynecologic malignancy; paraneoplastic cerebellar degeneration; paraneoplastic neurological syndrome

 Full Text:

PDF

References

Binks S, Uy C, Honnorat J, Irani SR. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol 2022;22:19–31.

Shams’ili S, Grefkens J, De Leeuw B, Van Den Bent M, Hooijkaas H, Van Der Holt B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003;126:1409–18.

Venkatraman A, Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies – a review. Ann Clin Transl Neurol 2016;3:655–63.

Rojas I, Graus F, Keime-Guibert F, Reñé R, Delattre JY, Ramón JM, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000;55:713–5.

Ko MW, Dalmau J, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 2008;28:58–68.

Crino PB, Galetta SL, Sater RA, Raps EC, Witte A, Roby D, et al. Clinicopathologic study of paraneoplastic brainstem encephalitis and ophthalmoparesis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc 1996;16:44–8.

Md KP, Rosenblum MK, Ms HK, Posner JB. Paraneoplastic cerebellar degeneration.: I.A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992;42:1931.

Kumari VA, Gupta P, Srivastava MVP, Kumar L, Kriplani A, Bhatla N. Paraneoplastic cerebellar degeneration as the first evidence of malignancy: A case report. J Obstet Gynaecol Res 2014;40:1463–5.

Psimaras D, Carpentier AF, Rossi C, the PNS Euronetwork. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 2010;81:42–5.

Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JCG, Desestret V, Dubey D, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflammation 2021;8:e1014.

Vernino S, O’Neill BP, Marks RS, O’Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurologicaldisorders. Neuro-Oncol 2004;6:55–62.

Giometto B, Marchiori GC, Nicolao P, Scaravilli T, Lion A, Bardin PG, et al. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 1997;23:468–74.

Stark E, Wurster U, Patzold U, Sailer M, Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol 1995;52:814–8.

Widdess-Walsh P. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol 2003;63:187–90.

Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000;47:9–17.

DOI: http://dx.doi.org/10.31584/jhsmr.20241126

Refbacks

  • There are currently no refbacks.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.